| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/06/2005 | US6939862 Method for transferring nucleic acid into striated muscles |
| 09/06/2005 | US6939855 Anti-inflammatory compositions and method |
| 09/06/2005 | US6939854 enzyme inhibitors comprising peptide fragments, conjugated to boronic acids ,forming esters such as 1-amino-3-phenylpropylboronic acid (+)-pinanediol ester, used for prophylaxis of viral diseases |
| 09/06/2005 | US6939853 Administering glucagon-like peptide 1 (GLP-1) compound and an effective amount of an antidyslipidemic drug for therapy of dyslipidemia |
| 09/06/2005 | US6939852 Methods and compositions for the treatment of cerebral palsy |
| 09/06/2005 | US6939851 Serine proteinase inhibitors |
| 09/06/2005 | US6939850 Treatment of inflammatory diseases and/or diseases characterized by cell deaths, as well as cancers, autoimmune disorders, infections |
| 09/06/2005 | US6939847 Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators |
| 09/06/2005 | US6939846 Use of a polypeptide for treatment of pruritis in animals |
| 09/06/2005 | US6939714 Epithelial cell growth inhibitors |
| 09/06/2005 | US6939707 Isolated nucleic acid molecules which encode GAGE genes and uses thereof |
| 09/06/2005 | US6939700 Isolated human aminoacylase, nucleic acid molecules encoding human aminoacylase, and uses thereof |
| 09/06/2005 | US6939690 Polynucleotides encoding motilin homologs |
| 09/06/2005 | US6939680 Nucleotide sequences coding protein for use in the treatment and prevention of nervous system, dyskinesia, kidney, vascular, circadian rhythms and vision defects |
| 09/06/2005 | US6939677 useful for detection, diagnosis, and treatment of breast cancer; Human milk fat globule ( HMFG) |
| 09/06/2005 | US6939669 Expansion of hematopoietic cells using midkine or pleiotrophin |
| 09/06/2005 | US6939565 Protease inhibitors of the coagulation cascade isolated from Dysidea sponges |
| 09/06/2005 | US6939562 Collagen/polysaccharide bilayer matrix |
| 09/06/2005 | US6939559 Pharmaceutical composition for application to mucosa |
| 09/06/2005 | US6939557 biocompatible therapeutic article comprising, a macromer having polymerized end groups, precipitated human growth hormone, and a molecule or mixture of molecules which preferentially excludes proteins |
| 09/06/2005 | US6939548 Clostridium (C.) vaccination; fusion proteins; antibiotic resistance |
| 09/06/2005 | US6939546 Model for testing immunogenicity of peptides |
| 09/06/2005 | US6939545 Composition and method for treating inflammatory disorders |
| 09/06/2005 | US6939544 Antibodies against mouse pituitary tumor transforming gene carboxy-terminal (PTTG-C) peptides |
| 09/06/2005 | US6939543 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| 09/06/2005 | US6939542 Contacting vitreous humor with beta-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase, and/or protein kinase; thimerosal-free |
| 09/06/2005 | US6939541 Polypeptide for use in the treatment of viral diseases and cancer |
| 09/06/2005 | US6939540 nucleic acid encoding an angiogenic protein is administered to a cell in a region of a bone such that the nucleic acid is expressed to produce the angiogenic protein, whereby bone density or formation is enhanced within the region |
| 09/06/2005 | US6939539 present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons |
| 09/06/2005 | US6939534 Method to treat pulmonary hypoplasia in the newborn |
| 09/06/2005 | US6939532 Versatile hydrophilic dyes |
| 09/06/2005 | CA2267760C Stent lining |
| 09/06/2005 | CA2260769C Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg |
| 09/06/2005 | CA2250395C Eprosartan dihydrate and a process for its production and formulation |
| 09/06/2005 | CA2105652C Reducing wound scarring with antibodies to growth factors |
| 09/06/2005 | CA2097268C Absorbable bone sealant |
| 09/03/2005 | CA2457303A1 Transductin-1 and transductin-2 and applications to hereditary deafness |
| 09/01/2005 | WO2005080973A1 Diagnostics and therapeutics for diseases associated with human nuclear receptor nr5a1 (nr5a1) |
| 09/01/2005 | WO2005080972A1 Use of tweak modulators and inhibitors for the treatment of neurological conditions |
| 09/01/2005 | WO2005080597A1 Method for diagnosing colorectal cancers |
| 09/01/2005 | WO2005080568A1 Methods and compositions for treatment or prevention of secondary ischemic injury |
| 09/01/2005 | WO2005080559A1 Fungall cell wall degrading enzyme |
| 09/01/2005 | WO2005080558A1 Method of modulating cellular processes |
| 09/01/2005 | WO2005080553A1 Cell-associated physiologically active substance and cell culture supplement |
| 09/01/2005 | WO2005080433A2 Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
| 09/01/2005 | WO2005080423A1 Antifungal peptides |
| 09/01/2005 | WO2005080419A1 Polypeptide agent for inhibiting sars coronavirus and its derivatives and use thereof |
| 09/01/2005 | WO2005080409A1 Vectors having both isoforms of beta-hexosaminidase and uses of the same |
| 09/01/2005 | WO2005080353A1 Propenoyl hydrazides |
| 09/01/2005 | WO2005080338A2 New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins |
| 09/01/2005 | WO2005079860A1 New complexes |
| 09/01/2005 | WO2005079857A1 Galactomannans and/or glucomannans for increasing the bioavailability of active substances |
| 09/01/2005 | WO2005079849A2 Compounds for enhanced cancer therapy |
| 09/01/2005 | WO2005079848A2 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders |
| 09/01/2005 | WO2005079844A2 Use for interleukin-33 (il33) and the il-33 receptor complex |
| 09/01/2005 | WO2005079840A2 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 09/01/2005 | WO2005079839A1 Use of factor xiii for stimulating the perfusion of ischemic tissue |
| 09/01/2005 | WO2005079838A1 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| 09/01/2005 | WO2005079837A1 Methods of modulating il-23 activity; related reagents |
| 09/01/2005 | WO2005079836A1 Method for treating glaucoma |
| 09/01/2005 | WO2005079835A1 Anticancer agent containing bl angiostatin |
| 09/01/2005 | WO2005079834A1 Use of dmbt1 for capturing sulphate and phosphate group exposing agents |
| 09/01/2005 | WO2005079832A1 Use of hcnp peptides for the modulation of cardio-vascular physiology and diuresis |
| 09/01/2005 | WO2005079831A1 Use of hcnp peptides for the modulation of cardio-vascular physiology and diuresis |
| 09/01/2005 | WO2005079830A1 Inhibitors of amyloid fibril formation and uses thereof |
| 09/01/2005 | WO2005079829A2 Method for treating glaucoma |
| 09/01/2005 | WO2005079828A2 Treatment of abnormalities of the first metatarsophalangeal joint of the foot |
| 09/01/2005 | WO2005079827A2 Antitumor agent |
| 09/01/2005 | WO2005079826A1 Soothing agent and food for treating fatigue |
| 09/01/2005 | WO2005079822A2 Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds |
| 09/01/2005 | WO2005079821A1 Wound healing profile |
| 09/01/2005 | WO2005079810A1 USES OF ERβ MODULATORS |
| 09/01/2005 | WO2005079796A1 Pharmaceutical compositions based on anticholinergics and pegsunercept |
| 09/01/2005 | WO2005079794A1 Pharmaceutical compositions based on anticholinergics and pegsunercept |
| 09/01/2005 | WO2005079772A2 Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension |
| 09/01/2005 | WO2005079767A2 Means for modulation of the effects of opioid-like substances |
| 09/01/2005 | WO2005079766A2 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
| 09/01/2005 | WO2005079755A2 Interleukin-13 antagonist powders, spray-dried particles, and methods |
| 09/01/2005 | WO2005079593A1 Cysteine protease from ginger (zingiber) as a food improver and anti-inflammatory |
| 09/01/2005 | WO2005079508A2 Method and composition for angiogenesis inhibition |
| 09/01/2005 | WO2005079506A2 Systemic immune activation method using nucleic acid-lipid complexes |
| 09/01/2005 | WO2005079390A2 Inhibition of fgf signaling |
| 09/01/2005 | WO2005079284A2 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 09/01/2005 | WO2005079271A2 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer |
| 09/01/2005 | WO2005079269A2 Method of treating carcinomas |
| 09/01/2005 | WO2005065711A3 Mammalian receptor proteins; related reagents and methods |
| 09/01/2005 | WO2005060350A8 Diastereomeric peptides useful as inhibitors of membrane protein assembly |
| 09/01/2005 | WO2005059136A3 Dna-sequence and recombinant production of group 4 major allergens from cereals |
| 09/01/2005 | WO2005058953A3 Ogh fusion polypeptides and therapeutic uses thereof |
| 09/01/2005 | WO2005054290A3 Peptide hormones zalpha48 and zsig97 |
| 09/01/2005 | WO2005047476A3 Inhibition of retroviral replication through modulation of the host cell ubiquitylation |
| 09/01/2005 | WO2005041898A3 Blood substitutes |
| 09/01/2005 | WO2005040187A3 The use of sirna silencing in the prevention of metastasis |
| 09/01/2005 | WO2005033314A3 Method for the production of a cell and/or tissue and/or disease phase specific medicament |
| 09/01/2005 | WO2005026341A3 Plasminogen activators having reduced lysine binding capacity |
| 09/01/2005 | WO2005014049A3 Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| 09/01/2005 | WO2005004792A3 Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment |
| 09/01/2005 | WO2005002508B1 Macromolecular platinum chelates |
| 09/01/2005 | WO2005002504A3 Protection against vertical transmission of pathogenic infections |
| 09/01/2005 | WO2004103394B1 Method and compositions for nerve regeneration |